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Editorial 
New Advances in Alzheimer's Disease: From Biology to Therapy 
Alzheimer's disease (AD) is a devastating neurodegenerative disorder that results in the loss of memory and cognitive function,
and eventually dementia. AD is the most common cause of dementia and the eighth leading cause of death. Increasing age is 
the greatest risk factor for AD. Under the age of 65 the disease is rare, but it increases dramatically: the disease affects one in 
10 individuals over age of 65 and nearly half the population over age of 85. Some 4.5 million individuals in the United States 
have Alzheimer's disease [1, 2]. Scientists estimate that as the population continues to age and baby boomers reach retirement 
age and beyond, this number will triple by the year 2050. With this expected increase in the prevalence of AD there will be an 
increase in the financial burden caused by this condition. Thus, therapies aimed at the prevention and the treatments of AD are
desperately needed. This issue of Current Genomics is dedicated to the most recent advances in AD research, which began 100 
years ago when the disease was first described. 
A key neuropathological event in AD is the cerebral accumulation of an ~4kDa peptide termed A , the principle component of 
senile plaques. Amyloid plaques are formed by aggregates of amyloid- -peptides, 37-43 amino-acid fragments (predominantly 
A 40 and A 42) derived by serial proteolysis of the amyloid precursor protein (APP) by  - and  -secretase. APP more 
commonly undergoes a non-amyloidogenic processing by  -secretase that cleaves in the middle of the  -amyloid domain [3]. 
 -secretase has been identified as a novel membrane-tethered member of the aspartyl proteases, termed BACE [4, 5], while 
candidate  -secretases include ADAM 9, 10 and 17 (TACE, tumor necrosis factor-  c onverting enzyme) [6, 7]. Recent 
findings have shown that  -secretase is a complex of four proteins including presenilin, nicastrin/Aph2, Aph1 and Pen-2 [8].  
A central role for A  in AD pathogenesis is supported by studies of human genetics and data derived from both in vitro and in 
vivo models. In this issue of Current Genomics, Dr. Lacor reviews the findings that had led to development of the  -amyloid 
hypothesis, which states that A  accumulation is the initial step of a cascade of events starting with dysfunction of synaptic 
transmission and evolving in the degeneration of neuronal cells. A  can exist in a variety of different forms, including 
monomers, oligomers, protofibrils and fibrils. Dr. Lacor clearly discusses the toxicity of the different A  forms focusing on the 
synaptic toxicity of oligomeric species. These soluble toxins would account for the poor correlation between the number of 
amyloid plaques and disease progression, and could provide a unifying mechanism for AD pathogenesis.  
Since   -secretase processing of APP is the initial step of A  generation, BACE is an important target for therapeutic 
intervention. Drs. Cole and Vassar, who discovered BACE in 1999, review in this issue the biology of BACE with emphasis on 
its role in normal and disease conditions. Increasing evidence show that BACE is a stress-induced protease, which is 
upregulated in the brains of AD subjects, following experimental stroke and head trauma among other conditions. In addition to 
APP, other transmembrane proteins are processed by BACE raising the question of whether BACE inhibition could lead to 
serious side effects. The fact that BACE null mice are viable and fertile, and are apparently normal, at least early in life, 
suggests that the inhibition of BACE still represents a primary target for the treatment of AD.  
Gamma-secretase cleavage follows  -secretase processing of APP and results in the production of A . The inhibition of  -
secretase is another important target for anti-A  therapies. Gamma secretase activity requires the assembly of four proteins 
including presenilin, nicastrin/Aph2, Aph1 and Pen-2. In this issue Dr. Fraering reviews the role of each components in the 
regulation of  -secretase activity. Furthermore, he discusses the most recent findings on the structure of  -secretase. Electron 
microscopy (EM) and single particle image analysis of purified  -secretase complex revealed a globular structure with a low-
density central (and possibly water-containing) intramembrane chamber. Further structural studies are required to fully 
understand how  -secretase cleaves its substrates within the transmembrane domain. These studies will also help to develop  -
secretase inhibitors or modulators able to prevent A  generation without affecting the processing of other vital  -secretase 
substrates [9].  
Dr. Lleo’s article reviews the therapies currently available to the clinical neurologist for the treatment of subjects affected by 
AD. Unfortunately these treatments, acetylcholinesterase inhibitors and memantine, an NMDA antagonist, have only modest 
effects on the symptoms without affecting the progression of the disease. However, the advances in basic research reviewed in 
this special issue may facilitate the development of more effective drugs e.g. BACE and  -secretase inhibitors as well as 
therapies aimed to increase the clearance of A  toxic species.  
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